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large arteries, sometimes with coexistent VTE, 
and linked the events to hypercoagulability of 
the patients’ plasma.2,3 Some decades later, re‑
search on thrombophilia expanded by investi‑
gating families with frequent or unusual events 
of VTE. Today, due to this field of extensive re‑
search, the term thrombophilia is used to de‑
scribe a hemostasis disorder leading to an elevat‑
ed risk of developing VTE that can be inherited, 
acquired, or both. The well‑established factors of 
inherited thrombophilia are as follows: differ‑
ent loss‑of‑function mutations of the inhibitors 
of plasma coagulation that cause deficiencies of 
antithrombin (AT), protein C (PC), and protein 
Introduction Thrombosis is a common com‑
plex disease including atherothrombotic dis‑
eases (ATEs) and venous thromboembolism 
(VTE), which are highly frequent and are ma‑
jor contributors to morbidity and mortality in 
all developed countries.1 Clinically significant 
arterial thrombosis most typically occurs in 
the form of myocardial infarction (MI), isch‑
emic stroke (IS), or peripheral arterial occlu‑
sive disease, while venous thromboses include 
deep vein thrombosis and pulmonary embo‑
lism. The term “thrombophilia” was first used 
by Nygaard and Brown2 in 1937, when they de‑


















Atherothrombotic diseases (ATEs) and venous thromboembolism (VTE) have been traditionally considered 
to have a distinct pathogenesis. Today, a growing body of evidence on the pathophysiology of thrombus 
formation has convincingly proved that they share more mutual risk factors than previously recognized. 
It has been shown in a number of case‑control studies that there is a significant risk for a subsequent 
cardiovascular disease after VTE, although this risk is low or at most moderate. In the past 2 decades, 
the role of each inherited risk factor for VTE in relation to ATE has been intensively studied. Unfortunately, 
a large body of contradictory findings has been published that hinders consensus and transformation of 
knowledge into clinical practice. Complicated gene‑gene interactions, small sample sizes, heterogeneous 
genetic and environmental patient backgrounds, confounding factors, and varied methodological designs 
may have contributed to opposing findings. In the case of rare thrombophilias, conclusions must be 
summarized based on case reports or case series, as only few case‑control and cohort studies are available. 
In this review we focus on available evidence and controversies regarding the relationship between 
the classic inherited VTE risk factors (factor V Leiden, prothrombin 20210A, deficiencies of antithrombin, 
protein C, and protein S) and the risk of myocardial infarction (MI). We conclude that the risk of MI in 
patients with common inherited thrombophilia is generally modest. However, in patients with deficiencies 
of antithrombin, protein C, or protein S, the risk of MI or other ATEs is not negligible. A personalized 
clinical approach is suggested when testing for inherited thrombophilia in a patient with MI.
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have been traditionally considered to have dis‑
tinct pathomechanisms and risk factors, today, 
a growing body of evidence on the pathophys‑
iology of thrombus formation has convincing‑
ly questioned this dichotomy.19 Recent studies 
on the structure of arterial and venous throm‑
bi have led us to the conclusion that although 
the environments in which these clots form and 
propagate do not overlap, the composition of 
these thrombi have many shared features. In 
studies when arterial, intracoronary thrombi 
were extracted by thromboaspiration from pa‑
tients after MI, fibrin was found to be the main 
component of the thrombus, followed by lower 
platelet and red blood cell counts, and much few‑
er white cells.20,21 Notably, a microscopic analy‑
sis of venous thrombi revealed that they are also 
mostly composed of fibrin and entrapped red 
cells, with fewer platelets and leukocytes ran‑
domly dispersed, or concentrated in the cau‑
dal segment of these thrombi.19,22-24 Today, it is 
becoming clear that both arterial and venous 
thrombi are composed of a complex fibrin net‑
work and contain the same blood‑borne cells, 
and it is only the relative content of these ele‑
ments that may differ.19 It has been shown that 
genetic and environmental factors affect clot 
formation, structure, and stability.25 Based on 
common aspects in the pathophysiology of ve‑
nous and arterial clot formation, it is plausible 
to think that in the presence of inherited or ac‑
quired risk factors of VTE, arterial clots might 
form more readily as well.
The concept of increased risk of subsequent 
arterial events in patients with VTE has been 
a matter of debate and has been tested in a num‑
ber of case‑control studies.18 A systematic re‑
view and meta‑analysis of 17 studies showed 
that the risk of arterial cardiovascular events ap‑
peared to be higher in patients with unprovoked 
VTE as compared with controls (incidence rate 
ratio, 1.87; 95% CI, 1.32–2.65) and than in pa‑
tients with provoked VTE (incidence rate ratio, 
1.86; 95% CI, 1.19–2.89).26 In a large prospective 
cohort study including 4480 patients with VTE, 
it was found that patients have 2.2‑fold higher 
risk of subsequent cardiovascular disease as com‑
pared with controls (95% CI, 1.2–3.8).27 After con‑
founders (age, sex, body mass index, smoking, 
malignancy, chronic disease, genetic thrombo‑
philia, procoagulant markers) were also consid‑
ered, the risk estimate was no longer increased in 
patients as compared with controls. These results 
demonstrate that there is a risk for a subsequent 
cardiovascular disease after VTE, although this 
risk is low or at best moderate, and that the re‑
lationship between VTE and subsequent car‑
diovascular disease is not causal but can be ex‑
plained by common etiologic factors, including 
that of inherited thrombophilia.
The contributing role of each particular inher‑
ited risk factor for VTE to arterial thrombotic 
S (PS), gain‑of‑function mutations known as 
factor V Leiden (FVL) that result in resistance 
to activated PC (APC), and the guanine to ad‑
enine mutation at nucleotide 20 210 in the 3’ 
untranslated region of prothrombin gene (FI‑
I20210A). Further hereditary conditions, which 
may contribute to thrombotic phenotype are 
non‑O blood group, elevated factor VIII, IX, and 
XI levels, certain types of inherited fibrinogen 
disorders, and hyperhomocysteinemia.4 How‑
ever, some of these latter risk factors are only 
partly inherited, for example, heritability of hy‑
perhomocysteinemia is low, being rather related 
to several acquired conditions, predominantly 
to deficiencies of vitamin B12 and folic acid. The 
level of factor VIII is in part determined geneti‑
cally, but it is highly influenced by different clin‑
ical conditions (eg, acute phase reactions, VTE 
itself). Moreover, the cutoff value for elevated 
factor VIII is a matter of debate. Elevated lev‑
els of other clotting factors are rarely consid‑
ered as the cause of thrombophilia, and there‑
fore are not investigated routinely.
The discovery of hereditary thrombophilia 
risk factors raised considerable attention world‑
wide that initially led to a rising tendency to test 
for their presence in VTE. Unfortunately, wide‑
spread testing in nonselected patients, using var‑
ious methodologies suffering from preanalytical 
and analytical issues, and unanswered questions 
regarding the clinical implications of the results 
often left treating clinicians disillusioned by 
the usefulness of testing.3 Up‑to‑date indica‑
tions for thrombophilia testing in patients with 
VTE have been summarized in various guide‑
lines and reviews; however, validated guidance 
is still lacking on whom and what to test.5-15 As 
no single well‑standardized and widely accept‑
ed method exists for heritable thrombophilia 
screening, a list of investigations has to be per‑
formed in a patient suspected of thrombophilia. 
Thrombophilia screening usually includes tests 
for APC resistance or FVL, FII20210A, as well as 
assays for AT, PC, and PS. Some guidelines also 
recommend testing for elevated levels of FVIII 
and other clotting factors, members of the fibri‑
nolytic system, for example, plasminogen activa‑
tor inhibitor 1 (PAI‑1), together with the 4G/5G 
polymorphism in the PAI‑1 promoter; however, 
they have not been conclusively associated with 
VTE risk or require further validation.16
Thrombophilia testing in ATE is rather con‑
troversial. Most of the guidelines do not rec‑
ommend inherited thrombophilia testing in 
the case of arterial events, owing to the lack 
of evidence for their role in the pathogenesis 
of the disease and lack of justification regard‑
ing altered or intensified secondary preven‑
tion.3,17 However, a more recent concept of ath‑
erothrombosis suggests that arterial and venous 
thromboses have more in common than previ‑
ously recognized.18,19 Although ATE and VTE 
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23 374 controls, was the first to provide evi‑
dence that the presence of FVL is associated 
with a modest risk of MI (odds ratio [OR], 1.22; 
95% CI, 1.10–1.35). These results were confirmed 
by a more recent meta‑analysis, with a similar 
estimated risk of MI in FVL carriers (OR, 1.61; 
95% CI, 1.30–1.98).36 Thus, based on the 2 latter 
studies, the concept of FVL representing a mi‑
nor risk for MI in the general population can be 
concluded. Nevertheless, questions regarding 
the effect of FVL in important subpopulations 
(eg, in young individuals, smokers, women) re‑
main to be answered. Especially young patients 
aged less than 45 years have been in the focus 
of the attention based on the assumption that if 
MI occurs at an earlier age, atherosclerosis may 
play a minor role in the pathomechanism and 
any risk related to an inherited prothrombotic 
state might be more easily detected. 
One of the earliest case‑control studies in this 
subgroup of interest was published by Rosendaal 
et al44 who analyzed 84 women with MI young‑
er than 45 years of age and 388 control wom‑
en. The authors observed that FVL was associ‑
ated with a moderate risk of MI in young wom‑
en (OR, 2.4; 95% CI, 1.0–5.9). A major finding 
of this study was that smoking carriers of FVL 
presented a 32‑fold higher risk for MI as com‑
pared with nonsmoking noncarriers. The strong 
synergistic effect of smoking and thrombogen‑
ic risk factors (including FVL) was later con‑
firmed in young men (<52 years of age) with MI 
as well, thus it is not sex specific.45 The moder‑
ately increased risk of MI in younger populations 
with FVL was not unequivocally concluded lat‑
er by large case‑control studies (n >500 cases; 
TABLE 2).46,47 However, a study including the larg‑
est number of young MI patients (n = 1880) did 
confirm a significant moderate risk.48 Studies on 
the risk of MI in young women carrying FVL are 
mostly contradictory, and no clear conclusion 
can be drawn based on these reports as yet.44,47-49
Prothrombin G20210A and the risk of myo-
cardial infarction Overview of prothrombin 
G20210A mutation Prothrombin (FII), the pre‑
cursor of thrombin, is a vitamin K–dependent 
glycoprotein. Thrombin is the central enzyme 
of coagulation. Besides its predominant role of 
transforming fibrinogen to fibrin, it enhances its 
own generation, it activates factor XIII that leads 
to the production of clots that are more resis‑
tant to fibrinolysis, but it also displays anticoag‑
ulant activity and attenuates its own generation 
via the thrombomodulin/PC pathway.50 Dur‑
ing primary hemostasis, thrombin activates 
platelets via their proteinase‑activated recep‑
tor 1 (PAR‑1) or PAR‑4, which provides a proco‑
agulant phospholipid surface for coagulation to 
occur. Overall, 13 functions of thrombin have 
been described in hemostasis, and numerous 
nonhemostatic roles are also being discovered 
events has been studied intensively in the past 
2 decades. In this review we focus on available 
evidence and controversies regarding the rela‑
tionship between the classic inherited VTE risk 
factors (FVL, FII20210A, deficiencies of AT, PC, 
and PS) and the risk of MI.
Factor V Leiden and the risk of myocardi-
al infarction Overview of factor V Leiden mu-
tation The first report on APC resistance in 
1993 by Dahlbäck et al,28 followed by the identi‑
fication of the responsible genetic defect in factor 
V (FV G1691A) in 1994, opened a new chapter in 
the history of thrombophilia research.29-32 The ac‑
tive form of FV acts as a cofactor to activated fac‑
tor X in the process of converting prothrombin to 
thrombin. Factor V becomes activated by throm‑
bin and its active form is susceptible to cleavage 
and inactivation by APC.33 In the presence of FVL 
mutation, an amino acid change takes place at po‑
sition 506 of the mature protein (p.Arg506Gln, 
according to traditional nomenclature). As a re‑
sult, the APC cleavage site is altered, rendering 
FVL resistant to proteolytic inactivation, result‑
ing in a longer half‑life and increased generation 
of thrombin.34,35 The mutation of FVL is the most 
common thrombotic risk factor in the world, al‑
though it shows an uneven geographic distribu‑
tion ranging from being practically absent in na‑
tive Africans, Asians, Americans, or Australians, 
to being relatively frequent in populations of Eu‑
ropean origin, where allele frequency is generally 
between 3% to 7%, but may be as high as 10% or 
more in some populations.36-38 The relative risk 
of venous thrombosis associated with FVL has 
been clearly established (3‑ to 7‑fold risk increase 
for heterozygosity and up to 80‑fold risk increase 
for homozygosity as compared to wild type indi‑
viduals)13; however, the role of FVL as a risk fac‑
tor for arterial events, and particularly for MI, 
remains controversial.
Studies on the role of factor V Leiden mutation in 
the development of myocardial infarction Despite 
numerous studies and considerable efforts to un‑
derstand the association of FVL with MI risk, 
conflicting results have been published. As of 
January 2019, a comprehensive PubMed search 
of the literature on this topic from the past 
20 years resulted in more than 100 original 
publications. Unfortunately, no clear message 
emerges from these papers. Small sample sizes, 
heterogeneous genetic and environmental back‑
grounds, complicated gene‑gene interactions, 
confounding factors, and varied methodologi‑
cal designs may have contributed to the oppos‑
ing findings that were published. 
Six meta‑analyses were conducted on the sub‑
ject (TABLE 1). Earlier meta‑analyses were incon‑
clusive or showed no association between FVL 
carriership and the risk of MI.39-42 A meta‑anal‑
ysis by Ye et al,43 including 12 518 patients and 
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(embryonic development, wound healing, sep‑
sis, cancer propagation, fibrosis, inflammation, 
etc) (see Posma et al50 for a recent comprehen‑
sive review).
A common prothrombin gene mutation (FI‑
I20210A), identified in 1996, is the second most 
common heritable thrombophilic defect.51 This 
gain‑of‑function mutation results in enhanced 
recognition of cleavage site, increased processing 
of the 3’ end, increased mRNA stability, mRNA 
accumulation and protein synthesis, without al‑
tering the structure of the protein.52 As a con‑
sequence, the presence of the mutation leads to 
moderately increased levels of prothrombin that 
can be readily converted to thrombin when nec‑
essary. Heterozygous individuals for FII20210A 
have approximately 2‑ to 4‑fold increased risk 
of VTE, while this risk in homozygotes is some‑
what greater than 10‑fold.35 Similarly to FVL, 
the prevalence of the FII20210A mutation is de‑
pendent on ethnic background and shows geo‑
graphic variability. FII20210A, just as FVL, is al‑
most absent in the natives of Africa, America, 
Australia, and east Asia, while in northern Eu‑
rope, the allele frequency is approximately 1% 
to 2% and in Southern Europe it may reach up 
to 2% to 4%.13,35
Studies on the role of prothrombin G20210A mu-
tation in the development of myocardial infarc-
tion The association of FII20210A with the risk 
of MI has been studied in a number of conflicting 
and inconclusive reports. As the allele frequen‑
cy of this inherited risk factor of thrombophilia 
is fairly low in the general population, only very 
large case‑control studies or meta‑analyses are 
expected to reliably assess its association with 
MI risk. Main results of published meta‑analyses 
on the association of the FIIG20210A polymor‑
phism with MI are summarized in TABLE 3. Earlier 
meta‑analyses including fewer than 5000 cas‑
es found no significant effect of the mutation in 
the general population, but pointed out the pos‑
sibility that FII20210A might be a potential risk 
factor for MI or arterial ischemic events in young 
individuals.39,40,53 A study by Ye at al,43 including 
8211 cases and 12 356 controls, confirmed that 
the presence of FII20210A represents a signif‑
icant, but small risk for MI (OR, 1.25; 95% CI, 
1.05–1.50). A more recent report by Li et al54 (in‑
cluding a total of 33 studies with 13 488 cases and 
77 085 controls) showed a similar, significant as‑
sociation between FII20210A and MI in the al‑
lele model (A vs G; OR, 1.43; 95% CI, 1.18–1.72) 
with almost identical results in the heterozygote 
(GA vs GG) or dominant model (GA+AA vs GG) as 
well. In this study, authors have performed sub‑
group analyses and found that the association re‑
mained significant in those of Caucasian origin. 
An important conclusion from this work is that 
the FII20210A polymorphism is associated with 
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such as AT Cambridge II (p.Ala416Ser), AT Bu‑
dapest 3 (ATBp3, p.Leu131Phe), and AT Basel 
(p.Pro73Leu).61-63
Deficiencies of proteins C and S Proteins C and 
S are vitamin K–dependent plasma glycopro‑
teins.64 The domain structure of PC and PS is 
similar to other vitamin K–dependent coagula‑
tion factors, having a pre‑pro leader sequence, a 
γ‑glutamyl carboxylic acid domain, and epider‑
mal growth factor–like domains. Protein C is 
a 2‑chain protein in its mature form, and it con‑
tains an activation peptide domain and the ser‑
ine protease domain. The latter is responsible 
for its inactivation effect to activated FV and 
FVIII. Protein S is a single‑chain molecule that 
has a thrombin‑sensitive region and a C‑ter‑
minal region homologous to the sex hormone– 
–binding globulin—like domain. The free form, 
approximately 40% of total PS, which is not 
bound to its natural binding protein (C4bBP) 
acts as a cofactor for APC. Protein S also has 
APC‑independent anticoagulant effects that are 
not routinely tested in laboratories.65,66 Both APC 
and PS have roles in several nonhemostasis pro‑
cesses.67 Protein S is involved in cell proliferation 
and survival, apoptosis, regulation of inflamma‑
tory cytokine release, atherosclerosis, vasculo‑
genesis, and cancer development.68
Deficiencies of PC and PS were first described 
by Griffin69 and Comp70 in the 1980s. Both defi‑
ciencies may be caused by mutations that lead 
to quantitative disease (type I) or qualitative al‑
terations (type II). In PS deficiency, a laborato‑
ry phenotype of type III deficiency is also con‑
sidered, where a normal total PS antigen level is 
associated with low free PS antigen and low APC 
cofactor activity. Several reports have proposed 
that type I and III deficiencies may be phenotyp‑
ic variants of the same genetic disease.71 Molecu‑
lar genetic background of deficiencies of PC and 
PS is heterogeneous with a much lower muta‑
tion detection rate than it is observed in AT de‑
ficiency, at least partly due to methodological 
issues.64 Founder mutations are also known in 
PC deficiency, and the PS Heerlen is a relatively 
frequent variant.72-74
Studies on deficiencies of antithrombin, protein C, 
and protein S in arterial thrombotic diseases As 
congenital deficiencies of AT, PC, and PS be‑
long to rare diseases according to accepted def‑
initions,75 well‑designed, large clinical studies 
with an acceptable statistical power to find as‑
sociations with MI risk are still lacking. Multi‑
center studies may overcome this problem; how‑
ever, they are likely to be subjected to bias due 
to heterogeneous ethnicity. For this reason, here 
we focus not only on the association between de‑
ficiencies of AT, PC, and PS and the risk of MI, 
but the risk of other forms of arterial throm‑
botic events, mainly on IS as well. Nevertheless, 
the elderly (TABLE 3). It is plausible that MI events 
in young people are more likely to be attribut‑
able to genetic susceptibility to thrombotic risk 
than MI events in the elderly. It must be noted, 
however, that as compared with the number of 
younger individuals included in the analysis (n 
= 5294), only approximately half as many elderly 
patients with MI were available (n = 2174), dem‑
onstrating a possibility that elderly patients are 
lost through fatal MI or before the recruitment 
into case‑control studies. A potential survival 
bias, in fact, is an important limitation of most 
case‑control study designs published on this top‑
ic. In order to validate the above findings, large 
population (prospective) studies are warranted.
Another important question on the relation 
of common inherited thrombophilia risk factors 
(eg, FVL and FII20210A) and MI risk is wheth‑
er the same risk applies to all forms of ATE (eg, 
MI, IS, peripheral arterial occlusive disease) in 
a patient, or is this effect substantially different 
between the various manifestations of ATE. In 
a systematic review by Maino et al55 most mark‑
ers of hypercoagulability (including FVL) had a 
larger effect on the risk of IS as compared with 
MI, and this difference was more pronounced in 
young patients. Such predominant association 
with IS compared with MI was not as evident in 
the case of anticoagulant factors (eg, PC) caus‑
ing rare inherited thrombophilia.
Deficiencies of antithrombin, protein C, and 
protein S in arterial thrombotic disease An-
tithrombin deficiency Antithrombin is a serine 
protease inhibitor (serpin) and is the most im‑
portant circulating inhibitor of blood coagula‑
tion.56 It primarily inactivates the thrombin‑me‑
diated formation of fibrin clot and the genera‑
tion of thrombin by activated factor X. The ma‑
ture form contains an N‑terminal heparin‑bind‑
ing domain, a carbohydrate‑rich domain, and 
a C‑terminal serine protease–binding (reactive 
site) domain. According to its posttranslation‑
al modification, it has 2 isoforms differing from 
each other only in a glycosylation at Asn167.
Antithrombin deficiency was first described 
by Egeberg57 in 1965, and the first functional 
AT defect, named AT Budapest, was reported 
by Sas et al58 in 1974. The deficiency is classi‑
fied as type I (quantitative) and type II (qual‑
itative) deficiency. The latter group includes 
deficiency of the heparin binding site (IIH‑
BS), the reactive site, and mutations leading 
to pleiotropic effects are also known.59 Anti‑
thrombin deficiency in general is associated 
with the highest risk of VTE, with the excep‑
tion of the IIHBS type, which may confer a low‑
er VTE risk in heterozygous state.60 Molecular 
genetic background of AT deficiency is highly 
heterogeneous, having more than 200 muta‑
tions listed in the HGMD database; however, 
there are some prevalent founder mutations, 
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Case‑control and cohort studies on deficiencies of 
antithrombin, protein C, and protein S The num‑
ber of case‑control studies on deficiencies of AT, 
PC, and PS is rather low. AT Cambridge II in‑
creased the risk of MI by 5.66‑fold in a Span‑
ish study,76 while it was without effect on IS 
in the Chinese population.7 7 On the contrary, 
the effect of rare thrombophilia was negligible 
in a study involving 255 MI cases and 400 con‑
trol subjects in a recent study.78 When PC‑defi‑
cient individuals (n = 34) and nonaffected indi‑
viduals (n = 90) with ATE were compared, it was 
concluded that congenital PC deficiency contrib‑
uted to an earlier onset of the disease.79
There are 2 possible concepts when designing 
observational cohort studies in deficiencies of 
AT, PC, and PS. First, the detection of deficien‑
cies (usually as part of thrombophilia screening) 
in ATE cohorts, and second, the detection of ATE 
in deficient cohorts. Both approaches have their 
rationale. It is to be considered, however, that 
the clinical research questions and the conclu‑
sions drawn from them are different.
In the first type of cohort studies, only a mi‑
nor fraction of ATE patients are expected to 
have underlying deficiencies of AT, PC, or PS, 
particularly if the study involves a relatively low 
number of unselected patients. Therefore, these 
studies are often contradictory and inconclu‑
sive.80-83 Only a small proportion of ATE patients 
had deficiencies of AT, PC, or PS in most stud‑
ies recruiting low number of individuals,80-85 ex‑
cept for young Brazilian individuals with IS (n 
= 130), where the prevalence of PS deficiency 
was 11.5%.86 In the most recent study including 
IS patients older than 65 years, 10 out of 89, 5 
out of 99, and 8 out of 100 of tested patients 
had deficiencies of AT, PC, and PS, respective‑
ly. Nevertheless, this laboratory diagnosis led 
to a change in patient management in approxi‑
mately one‑third of the cases.87
According to the second concept of study de‑
sign, in which AT‑, PC‑ or PS‑deficient cohorts 
are investigated for ATE, the majority of pub‑
lished reports focus on AT deficiency. In this 
field, large cohort studies of 5 study groups are 
available.60,63,88-90 In the study by Alhenc‑Gelas et 
al,88 330 probands in France with AT deficiency 
and their relatives were recruited, and the prev‑
alence of ATE was 4.8% in the whole population 
at a mean age of 38 years at the first presenta‑
tion. The frequency of ATE was somewhat high‑
er in type IIHBS (ATBp3, AT Basel, and AT Toya‑
ma), as compared with other types. In a Finnish 
study, where AT Basel was a frequent variant, 
nearly 12% of patients had experienced ATE and 
among them 5 patients had IS before the age of 
45 years.63 Orlando registered ATE in 16 out of 
82 individuals with type IIHBS AT deficiency, 
and AT Basel showed the strongest association 
with the disease as well.90 In a study from Ger‑
many, 72 type IIHBS patients were registered 
as of today, by searching the literature using 
the terms “antithrombin or protein C or pro‑
tein S deficiency AND myocardial infarction 
or stroke or arterial thrombosis or arterial dis‑
ease,” the majority of the published studies are 
single case reports.
Case reports on deficiencies of antithrombin, pro-
tein C, and protein S In rare diseases, well‑writ‑
ten case reports may have an impact on the de‑
velopment of recommendations and clinical de‑
cision making if clinical and laboratory investi‑
gations provide evidence for the association be‑
tween the questioned parameter and the disease. 
In this review case reports were considered based 
on the following selection criteria: objective con‑
firmation of MI or IS diagnosis; data on AT, PC, 
or PS levels; publishing date is within the last 
20 years. Publications on acquired deficiencies 
of AT, PC, or PS were excluded. A total of 34 case 
reports were consistent with the above criteria, 
the most important details of which are sum‑
marized in Supplementary material, Table S1.
Practically all patients in these case reports 
were young; all but one patient were younger 
than 50 years of age at the first presentation 
with ATE. This may suggest that hereditary de‑
ficiencies of the natural anticoagulants are se‑
vere enough to cause early onset of thrombot‑
ic complications; however, it may also reflect 
the present clinical practice of not investigating 
thrombophilia in elderly MI or IS patients. Male 
and female patients were equally affected with 
ATE according to these reports. The presence of 
well‑known risk factors of ATE was excluded in 
most of the cases. Unfortunately, the timing of 
blood sampling for laboratory tests in some case 
reports has not been indicated, although it is rec‑
ommended that at least 6 weeks should elapse 
after the acute event to exclude the influence of 
acute phase reaction. In most cases anticoagu‑
lant drugs were withdrawn before AT, PC, PS 
measurements. In studies without genetic diag‑
nosis of deficiencies of AT, PC, or PS, the associa‑
tion between ATE and inherited form of the defi‑
ciency cannot be reliably confirmed. Family his‑
tories of the patients were not recorded in many 
cases, but there were some reports on multiple 
thrombotic episodes cosegregated with deficien‑
cies of AT, PC, or PS, confirming the presence of 
hereditary deficiencies in those families. In con‑
clusion, in young individuals with ATE, in the ab‑
sence of classic risk factors, the chance of detect‑
ing underlying deficiencies of AT, PC, or PS was 
not negligible. In families with these deficiencies 
not only VTE but also ATE might develop, and 
combined thrombosis (ie, ATE plus VTE) might 
be common. It is to be noted, however, that in 
the case of IS, the presence of patent foramen 
ovale or arteriovenous fistula (which may reflect 
venous origin of thrombotic complications) was 
not unequivocally excluded in these case reports.
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Meta‑analyses on deficiencies of antithrombin, pro-
tein C, and protein S Performing meta‑analysis 
in any rare disease is a challenging task. This is 
at least in part caused by the difficulties of de‑
termining the predictors and outcome variables, 
which vary considerably throughout the individ‑
ual studies. The heterogeneity in ethnicity is an‑
other issue, which makes the pooling of studies 
problematic. Literature search revealed  only 
2 meta‑analyses on the association between defi‑
ciencies of AT, PC, or PS and the risk of ATE (IS). 
The first study concluded that thrombophilia is 
more common in children who had IS as com‑
pared with healthy ones. Protein C deficiency 
increased the risk of IS with an OR of 6.49 (95% 
CI, 2.95–14.27).98 In a more recent meta‑analy‑
sis that investigated 1764 children with IS (in‑
cluding cerebral venous sinus thrombosis) and 
2799 controls, a significant association was found 
between IS and each studied rare thrombophilia 
trait (AT deficiency, OR, 7.06; 95% CI, 2.44–22.42; 
PC deficiency, OR, 8.76; 95% CI, 4.53–16.96, and 
PS deficiency, OR, 3.20; 95% CI, 1.22–8.40).99
In summary, based on the available case re‑
ports and results of population studies, laborato‑
ry investigation of rare inherited thrombophilia 
might be reasonable in selected patients with MI 
or IS. Factors that suggest underlying thrombo‑
sis risk factors are young age (<50 years), the lack 
of (or well‑treated) risk factors of atherosclero‑
sis, the lack of angiographic evidence of athero‑
sclerosis (ie, the presence of a coronary or cere‑
bral artery thrombus without major vessel ste‑
nosis), family member(s) with confirmed defi‑
ciencies of AT, PC, or PS, and family member(s) 
who had VTE or ATE at a young age.
Conclusion In conclusion, the risk of MI in 
the case of a patient with common inherited 
thrombophilia (FVL and FII20210A) is low or 
moderate at most. In patients with deficiencies 
of AT, PC, or PS, the risk of MI or other ATEs is 
not negligible, and seem to occur at a younger 
age as compared with the general population. In 
general, a personalized clinical approach is sug‑
gested when testing for inherited thrombophil‑
ia in a patient with MI. If the diagnosis of inher‑
ited thrombophilia influences the clinical man‑
agement of the patient and helps avoid the recur‑
rence of thrombosis, it is definitely worth test‑
ing. Whether or not the patient would benefit 
from antithrombotic prophylaxis must be decid‑
ed on the total thrombotic risk. The concept of 
combined antiplatelet and anticoagulant agents 
for the secondary prevention of atherothrom‑
botic events have been revisited in the era of di‑
rect oral anticoagulants as they have lower risk 
of intracerebral bleeding as compared with vi‑
tamin K antagonists. Nevertheless, future stud‑
ies and guidance are warranted to help identify 
patients who will benefit most from thrombo‑
philia testing and altered secondary prevention.
out of 236 patients with AT deficiency and ATE 
was associated with type IIHBS (7 out of 72 in‑
dividuals) more often than with other types 
(14 out of 236 individuals).60 In a Hungarian co‑
hort of 246 AT‑deficient individuals, ATE was 
associated more often with AT Basel (43%) and 
ATBp3 (10.5%) than with type I AT deficiency; 
the median age at first presentation was only 
29 years in AT Basel and 33 years in AT Bp3 het‑
erozygotes.89 In this cohort, ATE was reported in 
3 children; 2 of them had IS and in one of them 
both MI and IS were found in the case history. 
In 2 smaller cohort studies involving 26 patients 
from southern Italy, only 4 patients were regis‑
tered with type IIHBS AT deficiency and one of 
them had IS.91 In a study of 29 children from 
North America, no ATE was registered during 
the follow‑up.92
One can conclude from these studies that in 
patients with AT deficiency, ATE presents no‑
tably (approximately 20 years) earlier as com‑
pared with the general population. Another 
observation is that AT deficiency is a hetero‑
geneous disease from the point of view of clin‑
ical manifestations, as the association with 
ATE seems to be the strongest in the case of 
type IIHBS.
As for PC deficiency, only 2 papers includ‑
ing a  small number of patients were pub‑
lished.93,94 History of ATE was present in a con‑
siderable proportion of PC‑deficient individuals 
in these studies. Moreover, PC deficiency signif‑
icantly decreased the age at onset of symptoms 
of ATE in one of the studies. In hereditary PS de‑
ficiency, no association was found with ATE ac‑
cording to the single study available.95
In a  large family cohort study recruiting 
552 individuals belonging to 84 different kin‑
dreds and having deficiencies of AT, PC, or PS, 
the hazard ratio for ATE was significantly higher 
in individuals with deficiency as compared with 
those who were nonaffected (HR, 2.3; 95% CI, 
1.2–4.5).96 The risk of ATE was especially pro‑
nounced in young patients. When a subgroup 
analysis was performed, only deficiencies of PC 
and PS remained significant predictors of ATE 
under the age of 55 years.
In a cohort study including pooled data from 
4 independent family cohort studies, the preva‑
lence of ATE among 308 individuals with either 
AT, PC, or PS deficiency was 14%, which is high, 
although lower than that of VTE in the same 
group (56%).97 PC and PS deficiencies seemed to 
be more pronounced as compared with AT defi‑
ciency in ATE, and the risk conferred by deficien‑
cies of AT, PC, and PS was only slightly higher 
than in the case of FVL or FII20210A. According 
to these results, inherited thrombophilia showed 
an association with ATE. Moreover, the study 
draws attention to a possible synergistic effect 
of traditional risk factors and thrombophilia in 
the pathogenesis of ATE.
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